Dear IG Members,
How can we improve the dialogue between researchers and the public? What roles do information, GDPR regulations and trust play in this context? How can the pharmaceutical industries as exemplary case help to face the risks and side effects of technologies?
The 2nd interview, with Economist and SiFi Author Karl von Wendt, in the previosly mentioned extended series just went online:
Check it out!